Skip to main content

Table 1 Major demographic and baseline clinical features of all subjects in this study

From: Airway host-microbiome interactions in chronic obstructive pulmonary disease

Demographic and baseline clinical features Healthy Controls (N = 16) COPD Patients (N = 43)
Age, yearsa 55.0 (8.8) 65.0 (4.8)
Gender, n (% Male) b 11 (68.8) 31 (72.1)
Current Smoker, n (%) 8 (50.0) 16 (37.2)
Number of cigarette packs per year 34.4 (11.2) 50.9 (28.2)
GOLD Stage: I/II/III/IV, n (%) NA 2 (4.7)/19 (44.2)/16 (37.2)/6 (14.0)
Inhaled steroid use, n (%) NA 33 (76.7)
LABA use, n (%) NA 34 (79.1)
LAMA use, n (%) NA 35 (81.4)
Number of exacerbations per year NA 1.9 (1.4)
CAT score NA 21.8 (8.3)
SGRQ total score NA 49.0 (22.9)
mMRC score NA 2.1 (1.2)
Pre FEV1 (L) 3.0 (0.7) 1.1 (0.5)
Pre FVC (L) 4.1 (1.0) 2.8 (0.9)
Pre FEV1/FVC ratio 0.73 (0.0) 0.4 (0.1)
Post FEV1 (L) 3.1 (0.8) 1.2 (0.6)
Post FVC (L) 4.0 (0.9) 3.3 (1.0)
Post FEV1/FVC ratio 0.76 (0.0) 0.4 (0.1)
  1. a Continuous data present as mean (SD)
  2. b Categorical data present as number (proportion)
  3. GOLD Global Initiative for Chronic Obstructive Lung Disease, LABA long-acting beta-agonist, LAM long-acting muscarinic antagonist, CAT COPD Assessment Test, SGRQ St. George’s Respiratory Questionnaire, mMRC modified Medical Research Council, FEV1 forced expiratory volume in one second, FVC forced vital capacity